New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2012
06:55 EDTCRTX, CRTX, CRTX, ACOR, ACOR, ACOR, JNJ, JNJ, JNJ, DNA, DNA, DNA, LLY, LLY, LLY, MYL, MYL, MYL, IPXL, IPXL, IPXL, VRTX, VRTX, VRTX, NVS, NVS, NVS, AMLN, AMLN, AMLNInstitute for International Research to host a summit
4th Annual Government Programs Summit is being held in Baltimore on March 14-16.
News For AMLN;NVS;VRTX;IPXL;MYL;LLY;DNA;JNJ;ACOR;CRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 21, 2014
15:18 EDTVRTXPanel votes Vertex CF drug safe, works for R117H mutation, Bloomberg reports
Subscribe for More Information
08:32 EDTLLYFDA accepted NDA for empagliflozin plus
Subscribe for More Information
07:15 EDTNVS, LLYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
07:11 EDTVRTXFDA Pulmonary-Allergy Drugs Advisory Committe to hold a meeting
Subscribe for More Information
October 20, 2014
15:09 EDTNVSNovartis reports FDA advisory committee recommends approval of secukinumab
Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA voted unanimously to support the approval of AIN457, or secukinumab, a selective interleukin-17A inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. A Biologics License Application for secukinumab is currently under FDA review with an anticipated action date in early 2015.
12:36 EDTJNJOptions with decreasing implied volatility
Subscribe for More Information
08:14 EDTJNJPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
08:04 EDTMYLGerman fund pressured to sell Mylan stake over drug used in executions, FT says
Subscribe for More Information
07:26 EDTNVSFDA Dermatologic & Ophthalmic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
07:20 EDTMYLInternational Continence Society to hold annual meeting
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.
07:16 EDTDNAAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
October 17, 2014
16:55 EDTJNJStocks end volatile week lower amid oil price plunge
Subscribe for More Information
14:50 EDTNVSBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
10:51 EDTLLYOptions with increasing implied volatility
Options with increasing implied volatility: COV DISH HLT QEP GREK BKW BYI LLY DTV TIBX
10:37 EDTJNJOptions with decreasing implied volatility: ATLS JNJ XLNX JNK HYG
Subscribe for More Information
10:27 EDTVRTXVertex FDA panel expected to be positive at Piper Jaffray
Subscribe for More Information
10:26 EDTVRTXFDA panel asked to consider benefit of Vertex drug in younger CF patients
Subscribe for More Information
08:57 EDTJNJPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTJNJPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:02 EDTJNJCovidien granted preliminary injunction against Ethicon's Harmonic ACE+7
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use